派安普利單抗，Penpulimab，CAS: 2350298-92-7，AntibodySystem Laboratories

貨號：DHH02225

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-74831.html

別名：AK-105, CAS: 2350298-92-7

簡介：

派安普利單抗 Penpulimab 是一種 IgG1 抗 PD-1 單克隆抗體，具有抗腫瘤活性。

貨號：DHH02225

產(chǎn)品品牌：Antibodysystem

通用名：Penpulimab

純度：>95% by SDS-PAGE.

濃度：1mg/ml

Formulationicon：0.01M PBS, pH 7.4.

內(nèi)毒素：Please contact with the lab for this information.

別名：AK-105

靶點;物種：Human CD279/PDCD1/PD1

種類：Humanized

受體鑒定：IgG1-Kappa

CAS: 2350298-92-7

存儲條件：

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

參考文獻(xiàn)：

Penpulimab: First Approval. PMID: 34813051

Antibodies to watch in 2022. PMID: 35030985

Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers. PMID: 35165764

Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events. PMID: 35833116

Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203). PMID: 34327136

Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201). PMID: 35875118

Corrigendum: Successful treatment of a patient with multiple-line relapsed extensive-stage small-cell lung cancer receiving penpulimab combined with anlotinib: A case report. PMID: 36033531

Autoimmune hemolytic anemia in patients with relapsed Hodgkin's lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1. PMID: 35503192

Successful Treatment of a Patient With Multiple-Line Relapsed Extensive-Stage Small-Cell Lung Cancer Receiving Penpulimab Combined With Anlotinib: A Case Report. PMID: 35321433